Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
“Human Medicines” page
A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
US patent office grants patent claiming dosing regimen for TECFIDERA™ (dimethyl fumarate)
Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination.
TECFIDERA prescribing information
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS.
Association between beta-interferon exposure and hospital events in multiple sclerosis.
Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone.
Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin.
Rituximab for relapsing-remitting multiple sclerosis.
Effect of therapeutic horseback riding on balance and gait of people with multiple sclerosis.
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study.
The force awakens: insights into the origin and formation of microglia.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
The Effects of IFN-β 1a on the Expression of Inflammasomes and Apoptosis-Associated Speck-Like Proteins in Multiple Sclerosis Patients.
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Pages
« first
‹ previous
…
22
23
24
25
26
27
28
29
30
…
next ›
last »